TNFalpha antagonists in rheumatoid arthritis patients seen in everyday practice.
Falgarone
Géraldine
G
Duclos
Muriel
M
Boissier
Marie-Christophe
MC
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D000069285:Infliximab; D017410:Practice Guidelines as Topic; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D012219:Rheumatology; D012720:Severity of Illness Index; D012955:Societies, Medical; D016896:Treatment Outcome; D028761:Withholding Treatment
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000069285:Infliximab; D000068800:Etanercept